Acumen Pharmaceuticals Inc (ABOS)
3.92
-0.06
(-1.51%)
USD |
NASDAQ |
Mar 24, 16:00
3.90
-0.02
(-0.51%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 159.61M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -29.81% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.8117 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
Yahoo
03/20 16:01
Yahoo
02/15 12:07
MT Newswires
02/13 11:41
Globe Newswire
02/13 08:00
Globe Newswire
01/04 08:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 03/28/2023* | -- | Results | Q4 2022 | -- | -0.23 | -- | |
| 03/28/2023* | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 11/14/2022 | -- | Results | Q3 2022 | -0.26 | -0.20 | -28.34% | |
| 11/14/2022 | 04:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/15/2022 | -- | Results | Q2 2022 | -0.25 | -0.25 | 0.00% | |
| 08/15/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/16/2022 | -- | Results | Q1 2022 | -0.23 | -0.17 | -35.29% | |
| 05/16/2022 | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers. |
| URL | https://www.acumenpharm.com |
| Investor Relations URL | https://investors.acumenpharm.com/ |
| HQ State/Province | Virginia |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Mar. 28, 2023 (est.) |
| Last Earnings Release | Nov. 14, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 39.40M |
| Net Income (TTM) | -38.34M |
| Total Assets (Quarterly) | 203.26M |
| Total Liabilities (Quarterly) | 6.613M |
| Shareholders Equity (Quarterly) | 196.65M |
Ratings
Profile
Edit
| Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers. |
| URL | https://www.acumenpharm.com |
| Investor Relations URL | https://investors.acumenpharm.com/ |
| HQ State/Province | Virginia |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | Mar. 28, 2023 (est.) |
| Last Earnings Release | Nov. 14, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ABOS Tweets |